Loading clinical trials...
Loading clinical trials...
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hospira, now a wholly owned subsidiary of Pfizer
NCT07671846 · Cancer
NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more
NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more
NCT06689488 · Lung Cancer
NCT06079671 · Locally Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions